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http://www.biomedcentral.com/1472-6890/12/24RESEARCH ARTICLE Open AccessLack of MMP-9 expression is a marker for poor
prognosis in Dukes’ B colorectal cancer
Selja Koskensalo1, Jaana Hagström2, Nina Linder3, Mikael Lundin3, Timo Sorsa4, Johanna Louhimo1
and Caj Haglund1,2*Abstract
Background: Matrix metalloproteinases (MMPs) play a role in cancer progression by degrading extracellular matrix
and basement membranes, assisting in tumour neovascularization and in supporting immune response in cancer.
Methods: We studied the prognostic value of immunohistochemical expression of MMP-2, MMP-8, and MMP-9 in a
series of 619 colorectal cancer patients using tissue microarray specimens.
Results: Of the samples, 56% were positive for MMP-2, 78% for MMP-8, and 60% for MMP-9. MMP-9 associated with low
WHO grade (p < 0.001). In univariate analysis of Dukes’ B tumours, MMP-9 negativity associated with poor survival (p = 0.018),
and MMP-9 positivity was an independent prognostic marker in multivariate analysis of these tumours (p = 0.034).
Conclusion: Negative MMP-9 expression can predict poor prognosis in Dukes’ B colorectal tumours and may prove
useful for identifying patients, who should be offered adjuvant treatment.
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Colorectal cancer (CRC) is the third most common malig-
nancy in the world [1]. The most important prognostic
factor in colorectal cancer is stage of disease at diagnosis.
Other factors for poor prognosis are venous and lymph-
atic invasion, deficient healthy tissue margins at surgery,
obstruction or perforation of the bowel, and poor differen-
tiation at histology [2-5]. In addition to tumour-specific
factors, also host responses, such as intra- or peritumoral
inflammation and desmoplasia or reactive lymph nodes
can suppress tumour spread and predict better outcome
[6-8]. In cancer progression and spread, tumours must in-
vade their surrounding tissues, basement membranes
(BM), and extracellular matrix (ECM), must avoid the
host’s immunoresponse, and must ascertain their circula-
tion by neovascularization. In all these phenomena, matrix
metalloproteinases (MMPs) play an important role [9].
MMPs are zinc-dependent endopeptidases capable of
degrading both BM and ECM proteins and extracellular* Correspondence: caj.haglund@hus.fi
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distribution, and reproduction in any mediumadhesion molecules. MMP-9, also known as gelatinase B,
is able to degrade collagens IV (the main component of
BM) and V, gelatins, and elastin. MMP-2, also known as
gelatinase A, is able to degrade the same substrates as
MMP-9, but also collagens I, VII, X, fibronectin and
procollagenase-3 [9]. MMP-8, also called collagenase-2, is
able to degrade collagens I, II and III [10].
In CRC, MMP-2 immunoexpression associates with
advanced disease [11,12], and high MMP-2 expression in
cancer cells and the stroma associates with poor prognosis
[11,13]. MMP-9 correlates with metastatic disease
[11,14,15] and poor prognosis [14], although conflicting
findings exist [16]. MMP-8 is expressed in many cancer
types [17,18] and may protect against cancer spread by
regulating tumour metastasis [18].
In this study, we studied the prognostic value of MMP-2,
MMP-8 and MMP-9 immunoexpression in colorectal
cancer.Methods
Patients
Sample material came from 643 consecutive patients who
underwent surgery for CRC at the Department of Surgery,
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on account of incorrect final diagnosis (9 patients) or syn-
chronous multiple tumours (9 patients). Six cases were
excluded because of insufficient archival surgical tissue speci-
mens. Finally, 619 cases remained, 330 of them male.
Tumour staging was performed according to the modified
Dukes’ classification [19], with 91 tumours classified as Dukes’
stage A, 226 as stage B, 161 as stage C, and 145 as stage D.
For patients’ clinicopathological characteristics, see Table 1.
Clinical data were retrieved from patient records, and sur-
vival and cause of death data until March 2011 from the
Population Register Centre of Finland, and Statistics Finland.
For MMP-9, we also stained tissue microarray (TMA)
specimens from a validation series of 213 CRC patients
treated between 1998–2001, 82 of them male; 31 tumoursTable 1 Patient clinicopathological characteristics and their c
immunoreactivity in colorectal cancer patients assessed with
MMP-2
Clinicopathological Patients positive p-value Pati
variable (n=) (n) % (n
Gender 0.887
Female 272 153 56.3 2
Male 309 172 55.7 3
Age 0.107
< 65 years 244 146 59.8 2
≥ 65 years 337 179 53.1 3
Dukes’ stage 0.317
A 87 44 50.6 8
B 208 110 52.9 1
C 155 93 60.0 1
D 131 78 59.5 1
Dukes’ stage 0.066
A and B 295 154 52.2 2
C and D 286 171 59.8 2
Differentiation (WHO grade) 0.116
1 19 9 47.4 1
2 382 211 55.2 3
3 155 86 55.5 1
4 24 19 79.2 2
missing 1
Histologic type 0.680
Adenocarcinoma 512 288 56.3 4
Mucinous carcinoma 69 37 53.6 6
Tumour location 0.202
Colon 315 169 53.7 3
Rectum 263 155 58.9 2
missing 3
* = p-value significant.were classified as Dukes’ stage A, 70 stage B, 69 stage C,
and 41 stage D, with 201 of tumours being adenocarcin-
omas; with 7 being grade I, 161 grade II, 37 grade III, and
4 grade IV. Clinical data was retrieved, as for the main co-
hort, until October 2011.
Tissue samples and preparation of TMA blocks
Formalin-fixed and paraffin-embedded surgical tissue
samples were collected from the archives of the Depart-
ment of Pathology, University of Helsinki. Histopatho-
logically representative regions of tumour specimens were
defined and marked on H&E slides. Three cores from
each tumour block were sampled with 1.0 mm punchers
with a manual tissue microarrayer (Tissue Arrayer 1, Bee-
cher Instruments Inc., Silver Spring, MD, USA). Threeorrelation with MMP-2, MMP-8, and MMP-9
chi-square test
MMP-8 MMP-9
ents positive p-value Patients positive p-value
=) (n) % (n=) (n) %
0.496 0.574
57 194 75.5 257 158 61.5
01 235 78.1 301 192 63.8
0.343 0.197
28 183 80.3 238 142 59.7
20 246 76.9 320 208 65.0
0.148 0.100
2 63 76.8 83 57 68.7
97 163 82.7 206 138 67.0
37 99 72.3 138 77 55.8
32 104 78.8 131 78 59.5
0.116 0.016*
79 226 81.0 289 195 67.5
69 203 75.5 269 155 57.6
0.326 <0.001*
9 14 73.7 18 12 66.7
68 290 78.8 374 254 67.9
38 111 80.4 142 77 54.2
2 14 63.6 23 7 30.4
1 1
0.085 0.053
81 382 79.4 489 314 64.2
7 47 70.1 69 36 52.2
0.073 0.419
05 247 81.0 311 191 61.4
40 179 74.6 244 158 64.8
3 3
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from each patient. From each block, 4-μm slides were cut
and processed for immunohistochemistry.
Immunohistochemistry of MMP-2, MMP-8, and MMP-9
The Lab Vision Autostainer TM 480 (LabVision, Fremont,
CA, USA) served for immunohistochemistry. Specimens
were deparaffinized in xylene and rehydrated through
graded alcohol series. To retrieve antigen, samples were
heated in the pretreatment module of the autostainer in
Tris–HCl pH 8.5 buffer for 20 minutes at 98°C. The sam-
ples were incubated for 5 min in DAKO REAL Peroxidase-
Blocking Solution (DAKO, Glostrup, Denmark) for inacti-
vation of endogenous peroxidases. The sections were incu-
bated for one hour with a monoclonal primary MMP-2
antibody MS-806-PO (NeoMarkers) diluted 1:700, with a
polyclonal MMP-8 antibody 1:100 [20] or with a polyclonal
MMP-9 antibody RB-1539-R7 (NeoMarkers) 1:1500 and
reacted for 30 min with the Dako REAL EnVision™/HRP
detection system, Rabbit/Mouse (ENV) reagent. Between
each pair of steps the sections were rinsed with Tween-20/
PBS. The peroxidase staining was visualized with 3-amino-
9-ethylcarbatzole (Sigma-Aldrich, Inc., St. Louis, MO,
USA). Slides were counterstained with Meyer’s haematoxy-
lin, washed in tap water for 10 min, and mounted in aque-
ous mounting medium (Aquamount, BDH, Poole, UK).
Stainings of specimens without primary MMP-antibody
were used as negative controls. Gingival tissue was used as
positive control in MMP-8 stainings, and gastric tissue in
MMP-2 and MMP-9 stainings.
Scoring of immunostainings
MMP-2, MMP-8, and MMP-9 immunostainings were
scored by two independent investigators (S.K. and J.H.)
without knowledge of clinical outcome. In case of different
scores, the consensus score was determined. The interob-
server variation was low, below 5%. The intensity of cyto-
plasmic staining in cancer cells was evaluated: strong
intensity, scored as 3, moderate as 2, and weak as 1. Ab-
sence of positivity in all spots was scored as 0 (Figure 1).
Spots without cancer cells were excluded. For further ana-
lysis, the patients were divided into two groups, negative
(0) versus positive (score 1–3).Figure 1 Immunohistochemical scoring pattern of MMP-9 in colorectaStatistical analysis
Correlations between stainings and clinicopathological
variables were assessed with the χ2 test or Fisher’s exact
test when applicable. The Mann–Whitney U-test was
applied to determine the correlation between age and
the immunoreactivity. Life-tables were calculated with
the Kaplan-Meier method. The significance of the differ-
ence between groups was assessed with the log-rank test
or log-rank test for trend. Patients alive at the end of the
follow-up (March 2011) and patients who died from un-
related causes or postoperatively (within 30 days from
surgery) were censored. The Cox proportional hazards
model served for multivariate survival analysis. Clinical
variables included in the model as covariates were age,
Dukes’ stage, differentiation (WHO grade), tumour loca-
tion (colon or rectum), and tumour histology (adenocar-
cinoma or mucinous carcinoma).
The likelihood ratio test was applied for exclusion or
inclusion of significant variables. A p-value of 0.05 was
considered significant. Statistical analyses were per-
formed with SPSS 17.0 software.
Results
Tissue expression of MMP-2, MMP-8, and MMP-9
Immunostaining for MMP-2
Of 581 cases, MMP-2 immunoreactivity was observed in
325 (55.9%). In 56 patients (9.6%), MMP-2 immunoposi-
tivity was scored as strong, in 98 (16.9%) as moderate,
and in 171 (29.4%) as weak, whereas 256 (44.1%) lacked
any MMP-2 immunopositivity. MMP-2 positivity did not
correlate with clinicopathological variables (Table 1).
Immunostaining for MMP-8
Of 548 cases, MMP-8 immunoreactivity was noticed in
429 (78.3%). In 39 patients (7.1%), MMP-8 immunoposi-
tivity was scored as strong, in 153 (27.9%) as moderate,
and in 237 (43.2%) as weak, whereas 119 (21.7%) lacked
any MMP-8 immunopositivity. MMP-8 positivity showed
no correlation with clinicopathological variables (Table 1).
Immunostaining for MMP-9
Of the 581 cases, MMP-9 immunoreactivity was observed in
350 (60.2%). In 50 patients (8.6%), MMP-9 immunopositivityl cancer. A no expression, B mild, C moderate, D strong.
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(33.0%) as weak, whereas 208 (35.8%) lacked any MMP-9
immunopositivity. MMP-9 correlated with WHO grade
(p < 0.001); it was more often positive in high to moder-
ately differentiated tumours. MMP-9 immunopositivity
did not correlate with Dukes’ stage, but was more often
positive in local (Dukes’ A-B) tumours than in advanced
disease (p = 0.016 ) (Table 1).
In the validation series of 213 cases MMP-9 was posi-
tive in 167 (78.4%). In positive patients, in 12 (7.2%), theTable 2 Univariate analysis of correlations between preopera
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* = p-value significant.immunopositivity was scored as strong, in 41 (24.6%) as
moderate, and in 114 (68.3%) as weak. No correlation
appeared between clinicopathological variables and
MMP-9 immunoexpression.
Prognostic roles of MMP-2, MMP-8, and MMP-9
In univariate analysis, 5-year survival was 62.5% in
MMP-9-positive, and 52.2% in MMP-9-negative
patients, a difference that was significant (p = 0.015).
Advanced Dukes’ stage (p < 0.001), old age (p = 0.005),tive characteristics and survival with Kaplan-Meier life-

































Koskensalo et al. BMC Clinical Pathology 2012, 12:24 Page 5 of 7
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prognosis (Table 2). The association between elevated
MMP-9 immunoexpression and improved prognosis was
evident only in Dukes’ B tumours, but it was such a strong
prognostic factor that the association was significant in
analysis of the whole cohort (p = 0.018). In Dukes’A stage
5-year survival was 92.3% in MMP-9 positive and 87.1% in
MMP-9 negative patients (p = 0.417), in Dukes’ C patients
56.6% versus 50.3% (p = 0.618), and in Dukes’ D patients
6.8% versus 9.6% (p = 0.992).
In Cox stepwise multivariate analysis, age (p < 0.001),
Dukes’ stage (p < 0.001), location (p = 0.016), and differ-
entiation (p = 0.005) were all independent prognostic
factors (Table 3). In Dukes’ B tumours, MMP-9 positivity
was an independent prognostic factor (p = 0.034), as was
tumour location (p = 0.041).
In the validation series, 5-year survival was 64.8% in
MMP-9 positive patients compared to 63.5% in those
MMP-9 negative, (p = 0.418). In subgroup analysis of
Dukes’ stages there were no significant differences in
survival according to stage.
Neither MMP-2 immunoexpression (p = 0.477) nor
MMP-8 immunoexpression (p = 0.719) associated in uni-
variate analysis with prognosis.
Discussion
It is clinically relevant to identify a prognostic marker in
Dukes’ B (stage II) disease. This stage is classified as local
disease, but 20% will still die from this, with surgery cur-
ing 80%. We urgently need biomarkers to identify those
20% at risk in order to offer them adjuvant treatment.
Here we show that MMP-9 tumour expression is an inde-
pendent prognostic factor in Dukes’ B colorectal cancer.













Tumour location in rectum 5.815
Histologic type
MMP9
NS = not significant, RH = relative hazard, CI = confidence interval at 95% level.survival emerged. In Dukes’ B, the difference was so great,
that it affected analysis of the whole cohort. In Dukes’ B
and C of the validation series, we noticed poorer progno-
sis among patients with MMP-9 negative tumours, but
the differences were not significant.
The overall survival was better in the validation series.
The difference in survival may have several reasons.
First, pathologic routines have changed and more lymph
nodes are nowadays evaluated, which may lead to stage
migration. Second, the surgical technique has changed,
especially in rectal cancer treatment. Third, the more
frequent use of adjuvant treatment might have improved
survival.
Our results differ from those in a recent study of stage
II CRC in which high MMP-9 expression associated with
higher recurrence rate, shorter disease-free survival, and
also shorter disease-specific survival, but association
with disease-specific survival was not significant in
multivariate analysis [21]. In CRC patients, high MMP-9
expression has been associated with liver metastasis [22].
We also analyzed high versus low immunoexpression,
but found no association with survival (data not shown).
Elevated MMP-9 mRNA levels have been associated
with poor disease-free and overall survival [14]. On the
other hand, some studies using immunohistochemistry
have failed to show any correlation between MMP-9 and
survival or clinicopathological parameters [16,23]. In
other cancer forms, such as lung cancer, head and neck
squamous cell carcinoma, and gastric cancer, MMP-9
associates with poor prognosis [24-26]. Interestingly, in
early breast cancer, elevated MMP-9 associates with bet-
ter prognosis [27].
In cancer, the host response, like the intra- or peritu-
moral inflammation reaction or desmoplasia, can predictnostic factors in 558 colorectal cancer patients (MMP-9)
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degrading proteinases may play a defensive role by sup-
porting the immune/inflammatory response. Stromal ex-
pression of MMP-9 inversely associates with liver
metastasis and tumour infiltration in CRC [28]. Stromal
MMP-9 positivity also inhibits metachronous haemato-
genic metastasis in Dukes’ B and C colorectal cancer
patients [29]. Here, we did not evaluate stromal MMP-9
expression, because we used tissue arrays with punches
taken from cancerous regions, and our samples were un-
suitable for reliable stroma evaluation. The TMA is not
as reliable as analysis of whole tissue sections because of
intra-tumoural heterogenity of immunohistochemical
expression. However, the results of evaluation of TMAs
and those of whole tissue sections have been shown to
be in concordance [30].
Tumour expression of MMP-2 has been associated
with poor prognosis in colorectal [11-13,31], gastric [25],
ovarian [32], and breast cancer [33]. Here, we found no
correlation between MMP-2 immunoexpression and
clinicopathological variables or prognosis of CRC.
Results similar to ours have emerged in CRC [34].
Thereby the role of MMP-2 in CRC is still controversial.
In breast cancer, MMP-8 changes metastatic potential
in vitro [15], and in melanoma and lung cancer it inhi-
bits metastasis formation by modulating cancer cell in-
vasion and adhesion [14]. It was expected that MMP-8
might be a marker for improved prognosis in colorectal
cancer, but we noticed no association between MMP-8
immunoexpression and survival.
Conclusion
The role of MMP-9 immunoexpression in colorectal
cancer is dual; it plays a role in matrix degradation enab-
ling tumour invasion, but it also seems to act as a sup-
portive factor for hosts’ defensive mechanisms against
cancer spread. Here we show that immunoexpression of
MMP-9 is a promising prognostic marker in Dukes’ B
(Stage II) CRC, the group of patients for whom we need
new markers to identify those at risk who need adjuvant
treatment.
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